This study is testing a drug called orticumab to see if it can reduce inflammation in the coronary arteries (the blood vessels that supply the heart) in people who have had a heart attack. Participants will receive either orticumab or a placebo (an inactive substance) for 24 weeks. Researchers will compare how much the inflammation changes in the three main coronary arteries between the orticumab and placebo groups after 24 weeks. To join, you must be over 18 years old and have had a type-1 heart attack more than 180 days ago. The study aims to enroll 240 participants, but its current recruitment status is unclear.

Study design

This interventional study plans to enroll 240 participants. It compares orticumab to a placebo, meaning some participants will receive the active drug and others will receive an inactive substance.

What's involved

You will need to attend planned study visits, provide complete medical history, and discuss any changes to your non-study treatments with the study doctor. Treatment will last for 24 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 24 weeks, indicating follow-up for at least this duration after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.